Repurposing pomalidomide as a neuroprotective drug in an alpha-synuclein-based model of Parkinson’s disease
Michela Etzi, Maria Francesca Palmas, Chiara Burgaletto, Maria Antonietta Casu, Giuseppina Cantarella, Alfonso De Simone, Giuliana Fusco, Maria Cristina Cardia, Franceso Lai, David Tweedie, Michael Scerba, Neigel Greig, Augusta Pisanu, Anna Rosa Carta · FENS Forum 2024
Parkinson's disease (PD) is a complex pathology presenting with motor symptoms coupled with a variety of non-motor symptoms originating in the central nervous system or the periphery, resulting in a complex multisystem disease. The development of therapeutic approaches to slow or stop disease progression remains the greatest unmet therapeutic need for PD. The immune system plays a pivotal role in the central and peripheral pathology of PD, reacting to misfolded α‐synuclein with neuroinflammation and dysregulation of peripheral immune responses. Here, we tested the neuroprotective properties of
ePoster · Neuroscience